Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lung cancer detection via CT scan

This article was originally published in The Gray Sheet

Executive Summary

Among 484 asymptomatic individuals at risk for lung cancer who were diagnosed by low-dose CT in a study conducted from 1993 through 2005, the 10-year lung-cancer-specific survival rate was 80%. The study, published Oct. 26 in The New England Journal of Medicine, showed improved survival rates at 10 years in patients with clinical stage I lung cancer (88%), particularly those who underwent surgical resection within one month after diagnosis (92%). Currently in the U.S., 173,000 people are diagnosed with lung cancer each year, and 164,000 (95%) die from the disease, the report observes. Rates of detection and cost-effectiveness are comparable to those associated with mammographic screening for breast cancer, according to the study...

You may also be interested in...



Study Authors Discourage Widespread CT Screening For Lung Cancer

A study questioning the validity of expensive CT scans for patients at high risk for lung cancer contradicts previous research and dampens the momentum of policy aimed to encourage CT lung cancer screening

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024136

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel